12-09-2013 дата публикации
Номер: US20130237526A1
The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine Areceptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HTantagonist or the like), and the like. 150-. (canceled)52. The method according to claim 51 , wherein the antidepressant drug is a tricyclic antidepressant claim 51 , a tetracyclic antidepressant claim 51 , a selective serotonin reuptake inhibitor claim 51 , a selective noradrenalin reuptake inhibitor claim 51 , a dopamine reuptake inhibitor claim 51 , a serotonin-noradrenalin reuptake inhibitor claim 51 , a monoamine oxidase inhibitor or a serotonin 2 (5-HT) antagonist.53. The method according to claim 51 , wherein the antidepressant drug is a tricyclic antidepressant.54. The method according to claim 53 , wherein the tricyclic antidepressant is imipramine hydrochloride claim 53 , clomipramine hydrochloride claim 53 , amitriptyline hydrochloride claim 53 , nortriptyline hydrochloride claim 53 , amoxapine claim 53 , trimipramine maleate claim 53 , lofepramine claim 53 , lofepramine hydrochloride claim 53 , dosulepin hydrochloride claim 53 , protriptyline claim 53 , doxepin or desipramine hydrochloride.55. The method according to claim 51 , wherein the antidepressant drug is a tetracyclic antidepressant.56. The method according to claim 55 , wherein the tetracyclic antidepressant is maprotiline hydrochloride claim 55 , mianserin hydrochloride or setiptiline maleate.57. The method according to claim 51 , wherein the antidepressant drug is a ...
Подробнее